# Kempharm Probability Of Bankruptcy

KMPH | - USA Stock | ## USD 10.75 0.24 2.18% |

**M**, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease to (8.3

**M**).

## Kempharm Probability Of Bankruptcy Analysis

Kempharm's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years. 2020 | 2021 (projected) | |

Interest Expense | 4.79 M | 4.75 M |

Gross Profit | 13.29 M | 14.56 M |

Probability Of Bankruptcy | = | Normalized | | Z-Score |

## Current Kempharm Probability Of Bankruptcy | 7% |

Most of Kempharm's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kempharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Kempharm probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Kempharm odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Kempharm financial health.

The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

## Kempharm Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Kempharm is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Kempharm's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kempharm's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kempharm's interrelated accounts and indicators.

**Click cells**to compare fundamentals

The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

Compare to competition |

Based on the latest financial disclosure, Kempharm has a Probability Of Bankruptcy of 7.0%. This is 83.83% lower than that of the Healthcare sector and 87.24% lower than that of the Biotechnology industry. The probability of bankruptcy for all United States stocks is 82.43% higher than that of the company.

## Kempharm Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kempharm's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kempharm could also be used in its relative valuation, which is a method of valuing Kempharm by comparing valuation metrics of similar companies.Kempharm is currently under evaluation in probability of bankruptcy category among related companies.

## Kempharm Main Bankruptcy Drivers

2016 | 2017 | 2018 | 2019 | 2020 | 2021 (projected) | ||

Return on Average Assets | (0.17) | (0.68) | (1.85) | (1.74) | (1.17) | (1.26) | |

Total Debt | 91.98 M | 93.48 M | 82.05 M | 79.53 M | 70.35 M | 70.48 M | |

Total Liabilities | 103.58 M | 109.97 M | 93.31 M | 84.96 M | 77.62 M | 82.85 M | |

Current Liabilities | 6.64 M | 11.51 M | 12 M | 5.43 M | 7.54 M | 8.35 M | |

Total Assets | 84.89 M | 52.46 M | 26.75 M | 10.51 M | 11.21 M | 11.5 M | |

Current Assets | 74.36 M | 45.9 M | 23.72 M | 6.97 M | 8.38 M | 8.6 M | |

Net Cash Flow from Operations | (29.77 M) | (33.1 M) | (54.2 M) | (23.74 M) | (1.94 M) | (2.09 M) | |

Weighted Average Shares | 912.32 K | 915.81 K | 1.12 M | 1.85 M | 3.98 M | 4.3 M | |

Weighted Average Shares Diluted | 912.32 K | 915.81 K | 1.12 M | 1.85 M | 3.98 M | 4.3 M |

## Kempharm Fundamentals

Return On Equity | (222.16) % | |||

Return On Asset | 6.45 % | |||

Profit Margin | (74.21) % | |||

Operating Margin | 21.98 % | |||

Current Valuation | 328.5 M | |||

Shares Outstanding | 28.51 M | |||

Shares Owned by Insiders | 14.73 % | |||

Shares Owned by Institutions | 16.03 % | |||

Number of Shares Shorted | 3.55 M | |||

Price to Earning | (1.21) X | |||

Price to Book | 3.64 X | |||

Price to Sales | 13.16 X | |||

Revenue | 23.32 M | |||

Gross Profit | 11.98 M | |||

EBITDA | 5.39 M | |||

Net Income | (54.75 M) | |||

Cash and Equivalents | 75.92 M | |||

Cash per Share | 2.66 X | |||

Total Debt | 2.75 M | |||

Debt to Equity | 0.032 % | |||

Current Ratio | 20.70 X | |||

Book Value Per Share | 2.96 X | |||

Cash Flow from Operations | (2.5 M) | |||

Short Ratio | 6.11 X | |||

Earnings Per Share | (6.83) X | |||

Number of Employees | 22 | |||

Beta | 3.36 | |||

Market Capitalization | 306.74 M | |||

Total Asset | 54.59 M | |||

Retained Earnings | (252.18 M) | |||

Working Capital | 45.74 M | |||

Current Asset | 54.08 M | |||

Current Liabilities | 8.34 M | |||

Z Score | 61.0 |

## About Kempharm Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kempharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kempharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kempharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.
## Be your own money manager

Our tools can tell you how much better you can do entering a position in Kempharm without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.## Did you try this?

### Run ETF Directory Now

## ETF DirectoryFind actively traded Exchange Traded Funds (ETF) from around the world |

All Next | Launch Module |

## Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kempharm using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.## Build Optimal Portfolios

### Align your risk with return expectations

Please see Kempharm Piotroski F Score and Kempharm Altman Z Score analysis. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

## Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.

Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges | Go | |

Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | Go | |

Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | Go | |

Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk | Go | |

Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing | Go |

The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.